Price$1.07+0.03 (+2.88%)
01:30 PM07:45 PM
News · 26 weeks44+33%
2025-11-022026-04-26
Mix3490d
- Insider13(38%)
- SEC Filings10(29%)
- Earnings5(15%)
- Other3(9%)
- Offering2(6%)
- Leadership1(3%)
Latest news
25 items- SECSEC Form DEFA14A filed by Lucid Diagnostics Inc.DEFA14A - Lucid Diagnostics Inc. (0001799011) (Filer)
- SECSEC Form DEF 14A filed by Lucid Diagnostics Inc.DEF 14A - Lucid Diagnostics Inc. (0001799011) (Filer)
- PRLucid Diagnostics to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 14, 2026Conference Call and Webcast at 8:30 AM ETNEW YORK, April 30, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that it will host a business update conference call and webcast on Thursday, May 14, 2026, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update and discuss the Company's operations and growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's first quarter 2026 financial results.
- INSIDERAmendment: New insider Lee Victoria Tou-Ho claimed ownership of 650,000 shares (SEC Form 3)3/A - Lucid Diagnostics Inc. (0001799011) (Issuer)
- SECLucid Diagnostics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Lucid Diagnostics Inc. (0001799011) (Filer)
- PRLucid Diagnostics Announces Closing of $18 Million Underwritten Offering of Common StockNEW YORK, April 24, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced the closing of its previously announced underwritten registered direct offering of 18,000,000 common shares at a purchase price of $1.00 per share, anchored by a $15 million investment from a fundamental institutional investor with support from a large existing shareholder. The gross proceeds from the offering, before deducting underwriting discount
- SECSEC Form 424B5 filed by Lucid Diagnostics Inc.424B5 - Lucid Diagnostics Inc. (0001799011) (Filer)
- SECLucid Diagnostics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Lucid Diagnostics Inc. (0001799011) (Filer)
- PRLucid Diagnostics Announces $18 Million Underwritten Offering of Common StockNEW YORK, April 23, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced the pricing of an underwritten registered direct offering of 18,000,000 common shares at a purchase price of $1.00 per share, anchored by a $15M investment from a fundamental institutional investor with support from a large existing shareholder. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other e
- SECSEC Form PRE 14A filed by Lucid Diagnostics Inc.PRE 14A - Lucid Diagnostics Inc. (0001799011) (Filer)
- INSIDERSEC Form 3 filed by new insider Lee Victoria Tou-Ho3 - Lucid Diagnostics Inc. (0001799011) (Issuer)
- PRLucid Diagnostics to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare ConferenceNEW YORK, April 9, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Thursday, April 16, 2026 at 10:15 AM EDT. The fireside chat will be webcast live and available via the Investor Relations Section of the Lucid Diagnostics website or by clicking here. A
- PRPAVmed Appoints Joseph Virgilio to Lead Relaunched Medical Device PortfolioMedtech industry veteran to oversee development and commercialization of PAVmed's current and future medical device portfolio.Octeris, Inc. subsidiary formed to advance endoscopic esophageal imaging technology recently licensed from Duke University.NEW YORK, April 2, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it has appointed medical technology industry veteran Joseph Virgilio as Senior Vice President and Chief Business Officer, Medical Devices to oversee the development and commercialization of PAVmed's cur
- PRPAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial ResultsPAVmed strengthened its capital structure and relaunched its medical device portfolio under new leadership Veris Health advanced strategic partnership with OSU and progressed implantable physiological monitor toward FDA submissionLucid Diagnostics expanded EsoGuard healthcare system access and clinical evidence base Conference call and webcast to be held today, March 30, at 8:30 AM ESTNEW YORK, March 30, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagno
- SECSEC Form EFFECT filed by Lucid Diagnostics Inc.EFFECT - Lucid Diagnostics Inc. (0001799011) (Filer)
- SECSEC Form 424B5 filed by Lucid Diagnostics Inc.424B5 - Lucid Diagnostics Inc. (0001799011) (Filer)
- SECLucid Diagnostics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Lucid Diagnostics Inc. (0001799011) (Filer)
- PRLucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial ResultsProcessed 3,664 EsoGuard® tests and recognized 4Q25 revenue of $1.5 millionExpanded EsoGuard access with U.S. Department of Veterans Affairs contract award and strengthened clinical evidence with positive data from the largest reported real-world experience of esophageal precancer detectionConference call and webcast to be held today, March 26, at 8:30 AM ESTNEW YORK, March 26, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM) ("PAVmed"), today provided a business update for the Company and reported financial results for the fourth quarter and full
- SECSEC Form 10-K filed by Lucid Diagnostics Inc.10-K - Lucid Diagnostics Inc. (0001799011) (Filer)
- PRPAVmed to Hold Fourth Quarter and Full Year 2025 Business Update Conference Call and Webcast on March 30, 2026Conference Call and Webcast at 8:30 AM ETNEW YORK, March 16, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Monday, March 30, 2026, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update and discuss the Company's operations and growth strategy. In addition, Dennis McGrath, PAVmed's President and Chief Financial Officer, will discuss the Company's fourth quarter 2025 financial r
- PRLucid Diagnostics to Hold Fourth Quarter and Full Year 2025 Business Update Conference Call and Webcast on March 26, 2026Conference Call and Webcast at 8:30 AM ETNEW YORK, March 12, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that it will host a business update conference call and webcast on Thursday, March 26, 2026, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update and discuss the Company's operations and growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's fourth quarter 2025 financial results.
- INSIDERChief Executive Officer Aklog Lishan was granted 2,170,000 shares, increasing direct ownership by 148% to 3,636,627 units (SEC Form 4)4 - Lucid Diagnostics Inc. (0001799011) (Issuer)
- INSIDERDirector Matheis Dennis was granted 123,000 shares, increasing direct ownership by 18% to 788,443 units (SEC Form 4)4 - Lucid Diagnostics Inc. (0001799011) (Issuer)
- INSIDERDirector White Debra was granted 123,000 shares, increasing direct ownership by 109% to 235,800 units (SEC Form 4)4 - Lucid Diagnostics Inc. (0001799011) (Issuer)
- INSIDERDirector Sparks Ronald M was granted 123,000 shares, increasing direct ownership by 62% to 320,460 units (SEC Form 4)4 - Lucid Diagnostics Inc. (0001799011) (Issuer)
LUCD FAQ
7 questionsWhat does Lucid Diagnostics Inc. do?
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. It focuses on patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. The company's lead products include EsoGuard, a laboratory developed esophageal DNA test that examines individuals DNA molecules for the presence or absence of cytosine methylation; and EsoCheck, a cell collection device that collects cells of targeted region of...Where does LUCD stock trade?
Lucid Diagnostics Inc. (LUCD) is listed on NASDAQ.What sector and industry is LUCD in?
Lucid Diagnostics Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did Lucid Diagnostics Inc. go public?
Lucid Diagnostics Inc. (LUCD) completed its IPO in 2021.What are analysts saying about LUCD?
Lucid Diagnostics Inc. has had 6 recent analyst actions on file. The most recent action was from Ascendiant Capital: Buy with a $1600.00 price target on 2021-12-27. Recent price targets range from $1300.00 to $2100.00.What companies are similar to LUCD?
Notable peers in the same industry include SYK (Stryker Corporation), BSX (Boston Scientific Corporation), MMM (3M Company), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare LUCD side-by-side with any of them on Quantisnow.How can I track LUCD on Quantisnow?
Quantisnow aggregates Lucid Diagnostics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LUCD to receive live email and push alerts on every new disclosure.